Studies on the impact of modifications at the Gln-Trp site in RM2-based GRPR ligands

Abstract Background One of the most studied, and preclinically as well as clinically applied gastrin-releasing peptide receptor (GRPR) ligands represents the antagonist RM2 (DOTA-Pip5-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Sta13-Leu14-NH2). As an improved in vivo stability was observed for a RM2 an...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Sebastian Fischer, Lena Koller, Sandra Dominelli, Roswitha Beck, Hans-Jürgen Wester, Thomas Günther
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	SpringerOpen 2025-09-01
Cyfres:	EJNMMI Research
Pynciau:	RM2 Modified pharmacophore GRPR Antagonist Metabolic stability
Mynediad Ar-lein:	https://doi.org/10.1186/s13550-025-01241-7
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!